TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Activity of Mefloquine Against Urinary Schistosomiasis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Pregnant women after first trimester and before 28th week of pregnancy~* HIV negative~* Egg excretion of Schistosoma haematobium (mean \>10 eggs per mL urine)~* Asymptomatic (no signs of complicated Schistosomiasis, no severe anemia)~* Ability to comply with study protocol~Exclusion Criteria:~* Intake of anthelminthic or antimalarial drug within 2 months prior to inclusion~* Allergy to study drugs

- Gender: FEMALE
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Mefloquine (Type: EXPERIMENTAL): 15mg/kg mefloquine per dose Women receive two doses: One after the first trimester of pregnancy and the second at least one month after the first dose
- S/P (Type: PLACEBO_COMPARATOR): sulfadoxine-pyrimethamine IPTp will be administered following current WHO recommendations

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Vitamin D and Calcium Homeostasis for Prevention of Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1/PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Ethnicity: all ethnic groups~* Gender: men and women~* Age~  1. Lower age limit: 40 years inclusive~ 2. Upper age limit: NONE~* BMI~  1. Lower BMI limit: 25 inclusive~ 2. Upper BMI limit: 40 inclusive~* Glucose Intolerance / Mild Diabetes defined as~  1. Fasting glucose ≥100 mg/dl OR~ 2. 2-hr glucose after OGTT ≥140 mg/dl OR~ 3. 5.8 ≤ Hemoglobin A1c ≤ 7~Major Exclusion Criteria:~* Diabetes requiring pharmacotherapy~* Smoking~* Hyperparathyroidism~* Hypercalcemia (Calcium \> 10.5 mg/dl)~* Kidney stone~* Pregnancy

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- 1 (Type: OTHER): Vitamin D3 2,000 IU daily plus Calcium Carbonate 400 mg twice daily
- 2 (Type: OTHER): Vitamin D3 2,000 IU daily plus Calcium-Placebo twice daily
- 3 (Type: OTHER): Vitamin D3-Placebo plus Calcium Carbonate 400 mg twice daily
- 4 (Type: OTHER): Vitamin D3-Placebo plus Calcium-Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: RTA 408 Ophthalmic Suspension for the Treatment of Ocular Inflammation and Pain Following Ocular Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Be greater than or equal to 18 years of age of either sex or any race;~2. Have undergone unilateral cataract extraction via phacoemulsification on the day prior to study enrollment/randomization;~3. Have a grade of ≥2 in anterior chamber cell score on day after surgery (Day 1);~4. Have a potential post-operative pin-hole visual acuity (VA) of greater than 1.0 logarithm of the minimum angle of resolution (logMAR) in the operative eye and fellow eye as measured using an Early Treatment for Diabetic Retinopathy Study (ETDRS) chart;~Exclusion Criteria:~1. Have any intraocular inflammation present in the study eye during the screening slit lamp examination;~2. Have a score greater than 0 on the Ocular Pain Assessment at Screening in the study eye;~3. Have an immunosuppressive disease or an autoimmune disease that in the opinion of the Investigator could affect the quality of the ocular surface;~4. Have active or chronic/recurrent ocular or systemic disease that is uncontrolled and will likely affect wound healing;~5. Have an intraocular pressure (IOP) ≤ 5 mmHg in either eye;~6. Require the use of a contact lens or a collagen shield within 72 hours of investigational drug treatment or during the study period in the study eye; be unwilling to discontinue use of contact lenses during study period in the study eye;~7. Require use of non-diagnostic topical ophthalmic solutions (other than perioperative mydriatics, anesthetics and antiseptics, prophylactic antibiotics, lid scrubs for mild blepharitis, or artificial tears for the management of dry eye) in the study eye for the duration of the study;

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Omaveloxolone Ophthalmic Suspension 1.0% (Type: EXPERIMENTAL): Patients will receive a single drop of Omaveloxolone Ophthalmic suspension 1.0% instilled into the study eye twice daily (approximately 12 hours apart) for 14 days, beginning 24 ± 6 hours after surgery
- Omaveloxolone Ophthalmic Suspension 0.5% (Type: EXPERIMENTAL): Patients will receive a single drop of Omaveloxolone Ophthalmic suspension 0.5% instilled into the study eye twice daily (approximately 12 hours apart) for 14 days, beginning 24 ± 6 hours after surgery
- Placebo (Type: PLACEBO_COMPARATOR): Patients will receive a single drop of vehicle for Omaveloxolone Ophthalmic suspension was instilled into the study eye twice daily (approximately 12 hours apart) for 14 days, beginning 24 ± 6 hours after surgery

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Evaluate Efficacy and Safety in Chinese Patients With Infantile-Onset Pompe Disease With One Year Alglucosidase Alfa Treatment

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion criteria:~* Subject's parents or legal guardians must provide written informed consent prior to any study-related procedures.~* Documented onset of Pompe disease symptoms up to 12 months of age (corrected for gestation if born before 40 weeks); diagnosis of Pompe disease confirmed by acid alpha-glucosidase enzyme deficiency from any tissue source and acid alpha-glucosidase gene mutations.~* Age 0-12 months at enrollment, defined as at the time of providing written informed consent.~* Cardiomyopathy (abnormal left ventricular mass indices \[LVMIs\], measured by echocardiography, abnormal value is defined as ≥65 g/m2 for patients up to 12 months old) confirmed by cardiologist at study site.~Exclusion criteria:~* Patient who has previously been treated with acid alpha-glucosidase.~* Patient who is participating in another clinical study using any investigational therapy.~* Conditions/situations such as:~* Clinical signs of cardiac failure with ejection fraction \< 40%.~* Respiratory insufficiency (oxygen saturation \< 90% or carbon dioxide partial pressure \> 55 mm Hg \[venous\] or \> 40 mm hydrargyrum \[arterial\] in room air or any ventilator use).~* Patients who are dependent on invasive or non-invasive ventilator support.~* Patients with major congenital anomaly or clinically significant intercurrent organic disease unrelated to Pompe disease.~* Patients not suitable for participation, whatever the reason, as judged by the Investigator, including medical or clinical conditions, or patients potentially at risk of noncompliance to study procedures.~The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

- Gender: ALL
- Minimum Age: 0 Months
- Maximum Age: 12 Months
- Healthy Volunteers: f

Study Arms:
- Alglucosidase Alfa therapy (Type: EXPERIMENTAL): Alglucosidase Alfa dose is calculated per kg body weight and administered once every 2 weeks for up to 52 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Phase 2 Study of ALN-RSV01 in Lung Transplant Patients Infected With Respiratory Syncytial Virus (RSV)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Single or bilateral lung transplant recipients~* Confirmed RSV infection~* Greater than 90 days post current lung transplant~* Rejection free for a minimum of 1 month~Exclusion Criteria:~* Antimicrobial therapy for known viral, bacterial, or fungal respiratory co-infection at the time of diagnosis~* Bronchiolitis obliterans syndrome (BOS) Grade 3 or any state BOS with FEV1 that has not been stable for at least 3 months~* Use of alemtuzumab within 9 months prior to screening; anti-thymocyte globulin(ATG) or thymoglobulin within 3 months of screening: concurrent use of \>= 0.3 mg/kg/day prednisone or equivalent as maintenance therapy~* active treament for acute graft rejection

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): ALN-RSV01
- 2 (Type: PLACEBO_COMPARATOR): Normal saline

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Safety and Immunogenicity of V710 in Adults With Kidney Disease on Hemodialysis (V710-005)(COMPLETED)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosed with end stage kidney disease and is on hemodialysis~* Female patients who are able to have children must have a negative urine pregnancy tests~Exclusion Criteria:~* Developed a serious infection within the past 12 months; allergy to the components of the vaccine~* Has been vaccinated with a live virus within the past 30 days or are scheduled to be vaccinated with a live virus in the next 60 days~* Received V710 vaccine before

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- V710 - Group 1 (Type: EXPERIMENTAL): V710 (60 mcg without MAA) on Day 1 and Day 28 followed by third dose of V710 or placebo on Day 180.
- V710 - Group 2 (Type: EXPERIMENTAL): V710 (60 mcg without MAA) on Day 1 and Placebo on Day 28 followed by third dose of V710 or placebo on Day 180.
- V710 - Group 3 (Type: EXPERIMENTAL): V710 (60 mcg with MAA) on Day 1 and Day 28 followed by third dose of V710 or placebo on Day 180.
- V710 - Group 4 (Type: EXPERIMENTAL): V710 (60 mcg with MAA) on Day 1 and Placebo on Day 28 followed by third dose of V710 or placebo on Day 180.
- V710 - Group 5 (Type: EXPERIMENTAL): V710 (90 mcg with MAA) on Day 1 and Day 28 followed by third dose of V710 or placebo on Day 180.
- Group 6 (Type: PLACEBO_COMPARATOR): Placebo on Day 1, 28 and 180.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Clinical Study to Investigate How Solifenacin Fluid is Taken up, How Long it Stays in the Body and How Effective and Safe it is in Treating Children Aged From 6 Months to Less Than 5 Years With Symptoms of Neurogenic Detrusor Overactivity (NDO)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Myelomeningocoele~* Documented diagnosis of NDO, confirmed by urodynamics~* DSD (detrusor sphincter dyssynergia)~* Practicing clean intermittent catheterization (CIC)~Exclusion Criteria:~* Know genitourinary condition (other than NDO) that may cause incontinence~* Bladder augmentation surgery~* Current faecal impaction~* Electro-stimulation therapy within 2 weeks prior to visit~* Subjects with the following gastro-intestinal problems: partial or complete obstructions, decreased motility like paralytic ileus, subjects at risk of gastric retention~* Reflux grade 3 to 5~* Current urinary tract infection

- Gender: ALL
- Minimum Age: 6 Months
- Maximum Age: 4 Years
- Healthy Volunteers: f

Study Arms:
- Solifenacin succinate (Type: EXPERIMENTAL): Children aged 6 months to less than 5 years were treated with sequential titrated doses of solifenacin up to 12 weeks in the Titration period after which a fixed dose of solifenacin was given for at least 40 weeks in the Fixed-dose assessment period. Children received solifenacin once daily during these 2 periods.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Sildenafil After the Fontan Operation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 8 years of age or older~* All participants must have had Fontan completion~Exclusion Criteria:~* Height less than 132 cm~* Unable to participate in exercise testing due to medical restrictions or physical limitations~* Fontan baffle obstruction or single lung physiology~* Coarctation of the aorta or neo-aorta (BP gradient \> 20 mmHg)~* Severe ventricular dysfunction assessed qualitatively by echocardiography~* Severe atrioventricular valvar regurgitation assessed qualitatively by echocardiography~* Presence of electronic pacemaker~* History of treatment with sildenafil in the six weeks prior to enrollment in study~* Patients with severe renal impairment~* Patients with severe hepatic impairment~* Patients taking medications that inhibit or induce Cytochrome P450 3A4 (CYP3A4) (including grapefruit juice and St. John's Wort)~* Patients taking alpha-blockers and nitrates~* Parents/guardians or subjects who, in the opinion of the investigator, may be non-compliant with study schedules or procedures

- Gender: ALL
- Minimum Age: 8 Years
- Maximum Age: 40 Years
- Healthy Volunteers: f

Study Arms:
- Sildenafil, then Placebo (Type: ACTIVE_COMPARATOR): Sildenafil will be given at a dose of 20 mg three times-a-day for six weeks followed by a six week washout period followed by placebo for an additional six weeks.
- Placebo, then Sildenafil (Type: ACTIVE_COMPARATOR): Placebo will be given for six weeks followed by a six week washout period followed by Sildenafil which will be given at a dose of 20 mg three times-a-day for six weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Mesalamine Pellet to Maintain Remission of Mild to Moderate Ulcerative Colitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Confirmed diagnosis of ulcerative colitis and in remission for at least 1 month~* Greater than 18 years of age~Exclusion Criteria:~* Allergy/intolerance to aspirin, mesalamine, or other salicylates~* Prior bowel surgery other than appendectomy~* Pregnancy, at risk of pregnancy, or lactating~* HIV or hepatitis B or C

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): Mesalamine pellets
- 2 (Type: PLACEBO_COMPARATOR): Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: To Assess the Effect of Lorcaserin Hydrochloride on Energy Metabolism and Food Intake

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Males or females aged between 18 and 65 years (inclusive)~2. Body Mass Index (BMI) is 27.0 to 45.0 kg/m2, inclusive~3. Able to give signed informed consent~4. Ambulatory and able to perform exercise program (Arena Healthy Lifestyle Program, see Appendix 1)~5. Eligible male and female patients must agree not to participate in a conception process~6. Considered to be in stable health in the opinion of the Investigator~Exclusion Criteria:~1. Prior participation in any study of lorcaserin.~2. Participants who are current smokers or have smoked within the previous 6 months. No smoking will be allowed during the study.~3. Clinically significant new illness in the 1 month before screening~4. Not suitable to participate in the study in the opinion of the Investigator including an existing physical or mental condition that prevents compliance with the protocol~5. Recent history (within 6 months before entering the study) of major depression, anxiety, or other psychiatric disease requiring treatment with prescription medication. SSRI's, SNRI's, and other medications must meet washout requirements.~6. Significant dislike or allergy to foods used during the food intake tests~7. History of any of the following cardiovascular conditions:~   * Myocardial infarction (diagnosed by cardiac enzyme\[s\] and/or diagnostic ECG), CVA, TIA or RIND within 3 months of screening; cardiac arrhythmia requiring medical or surgical treatment within 3 months of screening~  * Unstable angina~  * History of congestive heart failure caused by insufficiency, damage, or stenosis of any heart valve~  * History of pulmonary artery hypertension~8. Positive result of HIV, hepatitis B or hepatitis C screens~9. Recent treatment (i.e., within 1 month of the screening visit) with over-the-counter weight loss products or appetite suppressants (including herbal weight loss agents), or within 3 months with a prescription anti-obesity drug (e.g., phentermine, sibutramine, orlistat)~10. Participated in any clinical study with an investigational drug, biologic, or device within 1 month prior to screening

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Placebo BID (Type: PLACEBO_COMPARATOR): None
- Lorcaserin 10mg BID (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in the United Kingdom, as Part of Local Clinical Practice

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Signed consent obtained before any study-related activities (study-related activities are any procedure related to recording of data according to the protocol)~* Diagnosed with type 2 diabetes mellitus~* The decision to initiate treatment with commercially available oral semaglutide has been made by the patient/Legally Acceptable Representative (LAR) and the treating physician based on local label before and independently from the decision to include the patient in this study~* Male or female, age above or equal to 18 years at the time of signing informed consent~* Available glycated haemoglobin (HbA1c) value less than or equal to 90 days prior to the 'Informed Consent and Treatment Initiation visit' (Visit 1) or HbA1c measurement taken in relation with the 'Informed Consent and Treatment Initiation visit' (Visit 1) if in line with local clinical practice~* Treatment naïve to injectable glucose-lowering drug(s). An exception is short-term insulin treatment for acute illness for a total of 14 days or less.~Exclusion Criteria:~* Previous participation in this study. Participation is defined as having given informed consent in this study~* Treatment with any investigational drug within 30 days prior to enrolment into the study~* Mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: None

Study Arms:
- Patients with type 2 diabetes (Type: None): Adult patients with type 2 diabetes and naïve to injectable glucose-lowering treatment.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete